Hikma signs agreement with Sinclair IS Pharma to license Flammacerium for MENA region
- Jordan: Monday, March 18 - 2013 at 13:39
- PRESS RELEASE
Hikma Pharmaceuticals today announces the signing of an exclusive ten-year collaboration and licensing agreement with Sinclair IS Pharma for Flammacerium, its leading hospital product for the prevention and treatment of infections from severe burn wounds, in the Middle East and North Africa (MENA) region.
Under the terms of the agreement, Hikma will have the exclusive rights to register and market Flammacerium in 18 countries across MENA.
Said Darwazah, Hikma's CEO, said, "A key part of our MENA strategy is to continue expanding our network of global alliances to support us in strengthening our product portfolio. We are pleased to be partnering with Sinclair to bring Flammacerium, an excellent product which will strengthen our dermatology portfolio, to our patients in the MENA region."
Chris Spooner, CEO of Sinclair IS Pharma, said, "This collaboration further demonstrates Sinclair's ability to move our product portfolio into fast-growing emerging markets through regional partnerships. Hikma's presence and reputation across the MENA region will enable us to rapidly progress the adoption of Flammacerium."
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / 4C. AME Info FZ LLC / 4C is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.